KLRK1 and acute myeloid leukemia: Individuals with AML have low levels of cytotoxic NK cells, usually combined with decreased expression levels of activating receptors, for example, NKp46 (6), NKp30 (7), NKG2D (6) or DNAM-1 (8, 9).